Platelet aggregation induced by arachidonic acid and thromboxane generation in patients with hypertension or cerebrovascular disease.
The aggregability of platelets to arachidonic acid (AA) was investigated in 26 control subjects, 40 patients with essential hypertension, 20 patients with ischemic cerebrovascular diseases (CVD) not taking aspirin and 11 patients with CVD taking aspirin. The aggregability of platelets was evaluated on the basis of threshold concentrations of AA to induce irreversible platelet aggregation. The enhanced sensitivity of platelets to AA was observed more frequently in hypertensives and/or CVD patients not taking aspirin than in the controls. The relationship between platelet aggregation induced by AA and thromboxane B2 (TXB2) formation from AA or prostaglandin H2 (PGH2) in platelets was also studied in the subjects taking or not taking aspirin. It was proposed that the assessment of platelet aggregability with AA could provide a tool for identifying a subgroup of patients who might substantially benefit from the secondary preventive treatment with aspirin or other anti-platelet drugs. The clinical usefulness of this aggregation test for the management of the patients taking aspirin was also discussed.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001095:Arachidonic Acids / Q000097:blood / Q000494:pharmacology*; D001241:Aspirin / Q000627:therapeutic use; D001792:Blood Platelets / Q000378:metabolism; D002545:Brain Ischemia / Q000097:blood* / Q000188:drug therapy; D005260:Female; D006801:Humans; D006973:Hypertension / Q000097:blood* / Q000188:drug therapy; D066298:In Vitro Techniques; D008297:Male; D008875:Middle Aged; D010974:Platelet Aggregation / Q000187:drug effects*; D011463:Prostaglandins H / Q000097:blood; D013929:Thromboxane B2 / Q000097:blood*; D013931:Thromboxanes / Q000097:blood*
D001095:Arachidonic Acids; D011463:Prostaglandins H; D013931:Thromboxanes; D013929:Thromboxane B2; D001241:Aspirin